Accéder au contenu
Merck

Bi-Functional Peptides as a New Therapeutic Tool for Hepatocellular Carcinoma.

Pharmaceutics (2021-10-24)
Eric Savier, Lorena Simon-Gracia, Frederic Charlotte, Pierre Tuffery, Tambet Teesalu, Olivier Scatton, Angelita Rebollo
RÉSUMÉ

The interfering peptides that block protein-protein interactions have been receiving increasing attention as potential therapeutic tools. We measured the internalization and biological effect of four bi-functional tumor-penetrating and interfering peptides into primary hepatocytes isolated from three non-malignant and 11 hepatocellular carcinomas. These peptides are internalized in malignant hepatocytes but not in non-malignant cells. Furthermore, the degree of peptide internalization correlated with receptor expression level and tumor aggressiveness levels. Importantly, penetration of the peptides iRGD-IP, LinTT1-IP, TT1-IP, and RPARPAR-IP induced apoptosis of the malignant hepatocytes without effect on non-malignant cells. Receptor expression levels correlated with the level of peptide internalization and aggressiveness of the tumor. This study highlights the potential to exploit the expression of tumor-penetrating peptide receptors as a predictive marker of liver tumor aggressiveness. These bi-functional peptides could be developed for personalized tumor treatment.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-p32 Antibody, from rabbit, purified by affinity chromatography